"We’ll see a continued rise in...

 ...patient contributions to their specialty drug costs. In fact, patients’ out-of-pocket costs for specialty drugs have increased faster than GDP growth over the past decade."

—Dea Belazi, Pharm.D., M.P.H., president and CEO of AscellaHealth, spoke with AIS’s Radar on Specialty Pharmacy about trends in specialty drug benefit designs for the 2022 plan year.

 

Subscribers may read the Radar on Specialty Pharmacy article in which this quote appeared online. Learn more about subscribing to AIS Health's publications